Grace Breeding: how much time is really left before commercialization proof
Better field validation and tighter costs bought Grace Breeding time, but they did not close the funding gap. With NIS 474 thousand in cash and cash equivalents at the end of 2025, another raise in January 2026, and a contingent obligation still hanging over the company, the path to commercialization proof is still measured in months.
Time Was Bought, Not the Problem Solved
The main article already established that the science side moved forward: Maoz Bio 5 was chosen as the lead product after successful 2025 field trials, and the company has narrowed most of its effort around that product. This follow-up isolates the less glamorous but much more urgent question: how much time is really left before field progress starts to look like commercialization proof.
The number that organizes the whole story is not R&D expense. It is cash. Grace Breeding ended 2025 with no revenue, with negative operating cash flow of NIS 1.789 million, with an equity deficit of NIS 203 thousand, and with just NIS 474 thousand of cash and cash equivalents. Even after the equity raises completed during 2025 and another raise in January 2026, management explicitly says the company can continue operating for only a few months beyond the approval date of the financial statements if it does not secure additional funding sources.
That is the core point. The company is not buying itself a long proof runway. It is buying a short window of time. The operational improvement is real, but it mainly slowed the burn. It has not yet created a self-funding business, and it has not created a buffer that can absorb mistakes.
The chart shows both what improved and what did not. Operating cash burn fell sharply versus 2024, but even after that improvement it was still higher than the financing cash that came in during 2025. The gap between NIS 1.789 million of operating burn and NIS 1.383 million of financing inflow explains almost one for one why cash and cash equivalents fell from NIS 874 thousand to NIS 474 thousand.
The Real Cash Bridge
The right way to read 2025 is through an all-in cash flexibility lens, not through the income statement. On the P&L line, the loss from continuing operations improved to NIS 2.547 million from NIS 2.777 million in 2024. On the cash line, the company still burned NIS 1.789 million in operating activity, received NIS 1.383 million from financing activity, and finished the year with a very thin cash position.
| Item | NIS thousands | What it means |
|---|---|---|
| Cash and cash equivalents at end-2025 | 474 | The liquid cash actually left at year-end |
| Pledged bank deposit | 101 | On the balance sheet, but not the same as free cash |
| 2025 operating cash burn | -1,789 | The annual burn rate after the cost reset |
| 2025 financing inflow | 1,383 | Still did not cover operating burn |
| January 2026 private raise, gross | 610 | Adds time, but does not change the scale of the issue |
| Contingent payment to former employees | -227 | Can come back if the going-concern note is removed by August 31, 2026 |
Three layers matter here.
First layer: NIS 474 thousand of cash and cash equivalents at the end of 2025. At the 2025 burn rate, that is roughly three months of activity.
Second layer: There is also a NIS 101 thousand pledged bank deposit. It exists, but it is not the same thing as unrestricted cash the company can deploy freely.
Third layer: In January 2026 the company completed a private raise of NIS 610 thousand gross. That adds time, but even if one takes the full gross amount and adds it to year-end cash, visible liquidity reaches only about NIS 1.084 million before issuance costs and before additional obligations. Using the 2025 operating burn rate, that is roughly seven months.
This chart is only partly conservative. It excludes the pledged deposit, but it also does not deduct January 2026 issuance costs, and it does not assume any change in the 2026 burn rate. So it is not a forecast. It is an illustration: even on a relatively favorable read, the company is still measuring its proof window in months, not years.
What the 2025 Raises and the January 2026 Raise Really Mean
During 2025 the company lived on short oxygen rounds. A NIS 280 thousand gross raise was completed in March, another NIS 500 thousand in April, and another NIS 380 thousand in July. January 2026 added one more NIS 610 thousand gross round.
The aggregate of those four rounds is NIS 1.77 million gross. That is almost identical to the NIS 1.789 million of negative operating cash flow in 2025. Put differently, even after the cost cuts, a string of four equity rounds in less than a year was still mostly trying to keep pace with cash burn, not build a new financial base.
That matters because it is easy to read every raise as a solution. In practice, these raises look more like short extensions of runway. The report also notes that the January 2026 raise involved five different investors, including a senior officer and a relative of one of the directors. That does not make the money any less real. It does mean the company is still leaning on a close support circle to buy time, rather than showing a step-up to broad institutional funding or a commercial partner financing the next phase.
Management and Board Waivers Are a Subsidy, Not Balance-Sheet Strength
The efficiency plan did not stop at operations. It went directly through the compensation layer. In February 2024, against a backdrop of low cash, fundraising difficulty, and no meaningful financing completed, the company approved the departure of the prior CEO and COO. In their place, Moris Zilka was appointed CEO and Yossi Rave COO, both at 50% positions and at minimum wage.
That sounds like cost discipline, and it does save cash. But the filing adds a more important detail: the company itself states that the actual compensation paid to Zilka and Rave does not reflect market terms, and therefore it recognized about NIS 481 thousand in 2025 salary cost against equity. In plain terms, part of the company’s survival in 2025 was subsidized by management services provided below economic value.
| Layer | What was reduced in cash terms | Why it matters |
|---|---|---|
| CEO and Chair, Moris Zilka | 50% role at minimum wage | Saves cash now, but does not create a durable funding source |
| COO, Yossi Rave | 50% role at minimum wage | Same logic: it delays pressure, it does not solve the structure |
| Directors | Zilka and Rave waived director fees in 2025; the other directors accepted only the minimum statutory amount | The oversight layer is also subsidizing operations |
| Economic cost recognized in equity | NIS 481 thousand in 2025 | A partial substitute for cash, not new outside capital |
That point is critical because it changes how burn should be read. The company did not just cut expenses. It also received internal operating support. As long as that remains true, the reported cash burn does not necessarily tell the full story of what a normal compensation structure would look like.
The waivers also did not end with 2025. The report says Shaul Friedland signed another waiver in March 2026 so that his director compensation would remain at the minimum level in the first half of 2026. In other words, even after the January 2026 raise, the company was still not back to a normalized compensation structure.
The Contingent Obligation Did Not Disappear
On top of the thin cash balance, there is also a legal tail that has not gone away. Under a mediation arrangement with two former employees, the company already paid NIS 10 thousand, then NIS 50 thousand, and later another NIS 40 thousand. But that is not the end of the thread. Under the latest amendment, if the going-concern note is removed from financial statements published by August 31, 2026, the company must pay the former employees an additional roughly NIS 227 thousand indexed amount.
That may look like a small line item, but analytically it matters for two reasons.
The first is the amount itself. In a company of this size, NIS 227 thousand is not side noise. Relative to NIS 474 thousand of cash and cash equivalents at the end of 2025, it is close to half the year-end cash balance.
The second is the condition. The payment is not tied to higher sales. It is tied to the removal of the going-concern note. So a scenario of real improvement can itself bring another cash use back onto the table. That is not a company-threatening event by itself, but it is another cash claimant sitting against the same narrow bridge.
On the other side, if the condition is not met, the former employees retain the ability to bring a claim. So even in the weaker scenario, the issue does not disappear. It simply stays open.
What Has to Happen Now
This makes 2026 a test of more than one more good trial. The company has to show three things almost at the same time.
First, progress in Brazil and in the other trial channels has to start converting into measurable commercialization, not just better field validation. As long as 2025 ended with no revenue, funding remains the only bridge between the thesis and reality.
Second, the funding structure has to change from a sequence of small, management-intensive rounds into either a deeper financing event or a partnership that brings industrial funding rather than just time.
Third, the company has to keep moving without relying for too long on wage waivers, minimum director fees, and related-party equity benefits as a substitute for cash. That mechanism helped the company survive. It is not a business model.
Bottom Line
The encouraging part of the Grace Breeding story is that management did shrink the business intelligently: R&D expense fell to NIS 648 thousand, selling, general and administrative expense fell to NIS 1.812 million, and operating cash burn improved materially versus 2024. That means the efficiency plan did buy real time.
But it still bought only a short amount of time. End-2025 left the company with NIS 474 thousand in cash and cash equivalents. January 2026 added a NIS 610 thousand gross raise. At the same time, the company explicitly says it can continue operating for only a few months without additional funding, and there is still a contingent NIS 227 thousand obligation to former employees if the going-concern note is removed by the end of August 2026.
The thesis right now is straightforward: the scientific progress bought Grace Breeding an opportunity, but the path to commercialization proof is still dictated mainly by the cash balance. Until a deeper funding source arrives, or commercialization proof becomes measurable, the company remains in a story of months, small raises, and internal subsidization of the management layer.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.